Excerpt:
Depression affects an estimated 300 million people worldwide and is a leading cause of disability. Psilocybin has shown promise in reducing symptoms of depression after one or two doses with few side effects and no current evidence of causing addiction. However, studies published to date have not investigated factors that may moderate psilocybin’s effects, including type of depression, past use of psychedelics, dosage, and publication biases. To address this, a team of UK researchers examined databases looking for randomized controlled trials that compared psilocybin as a treatment for symptoms of depression with controls, such as placebo, niacin (vitamin B), or micro doses of psychedelics.
Article Link: MedicaXpress
Date: May 2, 2024
